Elite Pharmaceuticals to Present at The Banc of America
Securities 2005 Specialty Pharmaceutics Conference
NORTHVALE, N.J., July 21 /PRNewswire-FirstCall/ -- Elite Pharmaceuticals, Inc. (AMEX:ELI) is pleased to announce that the Company has been invited to present
at Banc of America Securities 2005 Specialty Pharmaceuticals Conference
scheduled for Wednesday, July 27 through Friday, July 29, 2005, at the
Southampton Inn in Southampton, New York. The theme of this year's conference
is "New Products, New Paradigms". Bernard Berk, Chairman & CEO, will give
Elite's presentation on Thursday, July 28th at 3:45 PM. Also representing the
Company will be Charan Behl, Ph.D., Elite's Head of Research & Development, and
Chris Dick, Senior Vice President of Business Development.
A replay of the presentation will be available on the Company's website at
http://www.elitepharma.com/ approximately 3 hours after the event and will be
available through August 12, 2005.
About Elite Pharmaceuticals Elite Pharmaceuticals is a specialty pharmaceutical company principally engaged
in the development of oral, controlled release products. The Company's strategy
includes developing generic versions of controlled release drug products with
high barriers to entry and assisting partner companies in the life cycle
management of products to improve off-patent drug products. Elite's technology
is applicable to develop delayed, sustained or targeted release capsules or
tablets. Elite has one product currently being sold commercially and a pipeline
of seven drug products under development in the therapeutic areas that include
pain management, allergy, cardiovascular and infection. The addressable market
for Elite's current pipeline of products exceeds $6 billion. Elite also has a
GMP and DEA registered facility for research, development, and manufacturing
located in Northvale, NJ.
This news release contains forward-looking statements, including those related
to the preliminary nature of the clinical program results and the potential for
further product development, that involve known and unknown risks, delays,
uncertainties and other factors not under the control of Elite or Pliva, which
may cause actual results, performance or achievements of the companies to be
materially different from the results, performance or other expectations
implied by these forward-looking statements. In particular, because substantial
future testing will be required prior to approval, the results described above
may not be supported by additional data or by the results of subsequent trials. These risks and other factors, including the timing or results of pending and
future clinical trials, regulatory reviews and approvals by the Food and Drug
Administration and other regulatory authorities, and intellectual property
protections and defenses, are discussed in the Elite's filings with the
Securities and Exchange Commission such as the 10K, 10Q and 8K reports. The
companies undertake no obligation to update any forward-looking statements. DATASOURCE: Elite Pharmaceuticals, Inc.
CONTACT: Dianne Will, Investor Relations, +1-518-398-6222, , for Elite Pharmaceuticals, Inc.
Web site: http://www.elitepharma.com/
|